Novartis agrees to buy Avidity Biosciences for $12bn
The acquisition will integrate Avidity’s late-stage neuroscience assets into Novartis.
UK regulators seize illegal weight loss drugs amid global pricing shake-up
Chugai acquires Renalys, enhancing its kidney disease portfolio
Excellergy eyes IgE therapy space as Xolair nears patent expiry
Roche in ongoing discussions with US government over drug pricing, CEO says
Demystifying the immune system with the help of AI-ML
Analysis
View More
Themes
View MoreHuawei’s three key steps to drive industrial intelligence forward and unleash AI’s full potential
During HUAWEI CONNECT 2025, Leo Chen, Senior Vice President, President of Enterprise Sales, Huawei, emphasised the focus is on how to harness AI’s full potential.
More themes
Data Insights
View MoreCell & gene therapy: the leading companies in recombinant AAV gene therapy revealed
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
Digital health and digital therapeutics (DTx) services and providers for the pharmaceutical industry
GlobalData Reports
View More
Digital Magazine
View MorePharma Technology Focus
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
First responders see AI and other advanced tech as essential
What does the EU Data Act mean for businesses?
Trump blames Covid-19 drugmakers for fuelling CDC turmoil
Oxford University and Ellison Institute link for AI vaccine research